Joshi Laxminarayan's expertise includes areas such as nano emulsion, extended release, and poorly soluble drug development
(CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) has appointed pharmaceutical scientist Joshi Laxminarayan as its chief scientific officer (CSO).
The firm, which specializes in a suite of cannabinoid and terpene blends in hard pill form for therapeutic applications, said Laxminarayan will be responsible for directing its strategic research and partnership program as well as overseeing the company's ongoing manufacturing and distribution operations.
READ: Canntab Therapeutics secures final tranche of C$3.7M private placement
Laxminarayan began his career in India as a bench chemist, and before his appointment as Canntab's CSO acted in a consultant role as director of the company's quality assurance & quality control, where he assisted with the research and development needed to formulate the company's current product line.
“His expertise in nano emulsion, extended-release, and poorly soluble drug development, has played a crucial role in the company's research and development with respect to cannabis oil inputs”, Canntab said.
In a statement, Canntab co-founder and chief executive Jeff Renwick, added: "Joshi has played an integral part in helping Canntab strengthen its competitive position and relevance, and distinguish itself in the pharmaceutical industry.
"His appointment as CSO is expected to evolve as we continue manufacturing, into a position where he can oversee not only our ongoing Research & Development, but also our day to day manufacturing and distribution operations. As Canntab enters the next phase of its growth, Mr Laxminarayan will be invaluable to our continued success, driving us closer to our goal of being the world leader in solid oral dose therapeutic cannabis solutions."
Canntab's aims for its cannabinoid formulations provide doctors, patients and consumers with medical-grade solutions incorporating all the features one would expect from prescription or over the counter medication sold in Canadian pharmacies.
Contact the author at [email protected]
Follow him on Twitter @Cal_Proac
